Financial Analysis: NKGen Biotech (NKGN) vs. Its Rivals

NKGen Biotech (NYSE:NKGN) is one of 280 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare NKGen Biotech to related businesses based on the strength of its valuation, dividends, profitability, analyst recommendations, earnings, institutional ownership and risk.

Profitability

This table compares NKGen Biotech and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
NKGen Biotech Competitors	-5,175.29%	-173.59%	-43.23%

Analyst Ratings

This is a summary of current ratings and recommmendations for NKGen Biotech and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0	0	0	0	N/A
NKGen Biotech Competitors	1581	4714	12209	235	2.59

As a group, “Biological products, except diagnostic” companies have a potential upside of 61.19%. Given NKGen Biotech’s rivals higher probable upside, analysts clearly believe NKGen Biotech has less favorable growth aspects than its rivals.

Insider & Institutional Ownership

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 20.0% of NKGen Biotech shares are owned by company insiders. Comparatively, 16.2% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares NKGen Biotech and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NKGen Biotech	$80,000.00	-$82.94 million	-0.08
NKGen Biotech Competitors	$566.46 million	-$32.27 million	-21.30

NKGen Biotech’s rivals have higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

NKGen Biotech has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, NKGen Biotech’s rivals have a beta of 1.08, suggesting that their average stock price is 8% more volatile than the S&P 500.

NKGen Biotech Company Profile

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.